The estimated Net Worth of Donald Abbey is at least $23.5 Million dollars as of 15 May 2024. Mr. Abbey owns over 948 units of Dexcom Inc stock worth over $207,259 and over the last 8 years he sold DXCM stock worth over $20,346,229. In addition, he makes $2,919,160 as Executive Vice President - Quality and Regulatory Affairs at Dexcom Inc.
Donald has made over 17 trades of the Dexcom Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 948 units of DXCM stock worth $64,910 on 15 May 2024.
The largest trade he's ever made was selling 11,604 units of Dexcom Inc stock on 21 November 2019 worth over $2,555,317. On average, Donald trades about 2,637 units every 65 days since 2016. As of 15 May 2024 he still owns at least 3,027 units of Dexcom Inc stock.
You can see the complete history of Mr. Abbey stock trades at the bottom of the page.
Donald M. Abbey serves as Executive Vice President - Quality and Regulatory Affairs of the Company. He has served as our Executive Vice President, Quality and Regulatory Affairs since January 2017 and served as our Executive Vice President, Quality from May 2016 to January 2017. From March 2007 to April 2016 , Mr. Abbey served in executive roles for Becton Dickinson (the acquirer of CareFusion in March 2015 which itself was spun off from Cardinal Health in 2009), including as Senior Vice President, Quality and Regulatory for Becton Dickinson from March 2015 to May 2016, as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion from May 2011 to March 2015, as Senior Vice President, Quality and Regulatory for CareFusion from October 2009 to May 2011, and as Senior Vice President, Quality and Regulatory for Cardinal Health from March 2007 to October 2009. Prior to 2007 Mr. Abbey held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare. Mr. Abbey began his career at Varian Medical and Boston Scientific holding positions of increasing responsibility in research and development and quality. Mr. Abbey received a B.S.E.E. from Washington State University and an M.B.A. from the University of Washington.
As the Executive Vice President - Quality and Regulatory Affairs of Dexcom Inc, the total compensation of Donald Abbey at Dexcom Inc is $2,919,160. There are 5 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
Donald Abbey is 53, he's been the Executive Vice President - Quality and Regulatory Affairs of Dexcom Inc since 2017. There are 18 older and 11 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Donald's mailing address filed with the SEC is 951, Calle Amanecer, San Clemente, Orange County, California, 92673, United States.
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff und Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: